Our vaccine research and development journey started with a strategic partnership with UMN Pharma in 2017. This collaboration escalated when UMN Pharma became a subsidiary of SHIONOGI in March 2020, thereby fast-tracking our work on vaccines against infectious diseases.
As a leading company in the infectious diseases field, we are concentrating resources on the development of vaccines and treatments for COVID-19, which caused the pandemic, leveraging external partnerships. Simultaneously, our own adjuvant research is paving the way for the development of our first COVID-19 vaccine.
Beyond this, we are involved in various other vaccine-related initiatives. In the infectious diseases domain, we are actively researching universal vaccines capable of dealing with viral mutations and next-generation intranasal vaccines. Additionally, in collaboration with external partners, we are advancing research on therapeutic vaccines for conditions like Hepatitis B.
Please check the details from the link below.